ReWalk Robotics Ltd. (DBA Lifeward) Announces The Centers For Medicare & Medicaid Services Is Deferring Its Final Decision On The Payment Rate For Personal Exoskeletons
Portfolio Pulse from Benzinga Newsdesk
ReWalk Robotics Ltd. (DBA Lifeward), announced that CMS has deferred its final decision on the payment rate for personal exoskeletons, affecting the pricing determination for ReWalk Personal Exoskeletons. The decision, part of CMS' HCPCS coding memorandum, means payments will continue on a case-by-case basis. Lifeward has delivered 35 Personal Exoskeletons to Medicare beneficiaries and remains committed to supporting pricing considerations for its stair-enabled ReWalk Exoskeleton.
March 01, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
CMS has deferred the final decision on the payment rate for Lifeward's ReWalk Personal Exoskeletons, affecting the company's pricing determination and potentially its revenue from Medicare beneficiaries.
The deferral by CMS on the payment rate decision directly impacts Lifeward's ReWalk Personal Exoskeletons, as payments will continue on a case-by-case basis. This uncertainty may affect the company's revenue projections from Medicare beneficiaries in the short term. However, the company's commitment to work with CMS and deliver additional units suggests a potential for positive resolution. The impact is neutral in the short term due to the ongoing uncertainty and the company's proactive stance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100